iX Biopharma Ltd. (SG:42C)
SGX:42C
Want to see SG:42C full AI Analyst Report?
Top Page
iX Biopharma Ltd.
(SGX:42C)
Select Model
Select Model
Rating:45Neutral
Price Target:
S$0.39
▼(-3.75% Downside)
Action:ReiteratedDate:04/18/26
The score is primarily weighed down by weak financial performance, including heavy leverage, persistent losses, and negative operating/free cash flow. Technicals provide partial support due to strong upside momentum and a positive MACD, but overbought RSI/Stoch increase short-term downside risk. Valuation contributes limited support given the provided P/E (0.000) and no dividend yield.
Positive Factors
Proprietary WaferiX platform
Owning the WaferiX sublingual wafer platform provides a durable product differentiation and IP foundation that supports licensing, formulation advantage for rapid delivery, and barriers to entry. This structural asset enables recurring licensing, manufacturing and partner-led commercialization opportunities over multiple product cycles.
Negative Factors
High financial leverage
Very high debt relative to equity materially increases financial risk and constrains strategic flexibility. Elevated leverage raises interest/service obligations, limits ability to fund development or commercialization internally, and increases vulnerability to revenue shortfalls or higher financing costs over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary WaferiX platform
Owning the WaferiX sublingual wafer platform provides a durable product differentiation and IP foundation that supports licensing, formulation advantage for rapid delivery, and barriers to entry. This structural asset enables recurring licensing, manufacturing and partner-led commercialization opportunities over multiple product cycles.
Read all positive factors
iX Biopharma Ltd. (42C) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$388.77M
Dividend YieldN/A
Average Volume (3M)15.11M
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth3.27%
EPS Growth43.59%
CountrySG
Employees35
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,050,720,000
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iX Biopharma Ltd. Business Overview & Revenue Model
Company Description
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and...
How the Company Makes Money
iX Biopharma makes money primarily by commercializing drug products that use its WaferiX sublingual wafer technology and by partnering with other pharmaceutical companies for distribution and market access. Key revenue streams include: (1) product...
iX Biopharma Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.77M | 5.96M | 5.91M | 14.39M | 1.75M |
| Gross Profit | 2.04M | 1.05M | 2.32M | 12.29M | -382.00K |
| EBITDA | -8.96M | -8.68M | -8.51M | -2.84M | -10.79M |
| Net Income | -10.14M | -10.79M | -9.62M | -4.60M | -8.23M |
Balance Sheet | |||||
| Total Assets | 11.28M | 14.62M | 24.93M | 28.52M | 18.86M |
| Cash, Cash Equivalents and Short-Term Investments | 866.00K | 1.77M | 6.52M | 13.49M | 6.21M |
| Total Debt | 5.90M | 5.20M | 4.34M | 4.41M | 4.24M |
| Total Liabilities | 10.92M | 10.28M | 9.08M | 8.77M | 7.15M |
| Stockholders Equity | 365.00K | 4.34M | 15.85M | 19.74M | 11.71M |
Cash Flow | |||||
| Free Cash Flow | -3.96M | -6.84M | -8.36M | 2.92M | -8.90M |
| Operating Cash Flow | -3.76M | -6.55M | -7.66M | 3.12M | -8.35M |
| Investing Cash Flow | -201.00K | 1.06M | -695.00K | -5.62M | -507.00K |
| Financing Cash Flow | 3.12M | 724.00K | 1.42M | 9.79M | 10.02M |
iX Biopharma Ltd. Technical Analysis
Positive
0.40
Price Trends
0.23
Positive
0.19
Positive
0.12
Positive
Market Momentum
0.05
Negative
76.43
Negative
83.53
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.23, and above the 200-day MA of 0.12, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 76.43 is Negative, neither overbought nor oversold. The STOCH value of 83.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42C.
iX Biopharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | S$38.55M | -10.60 | -8.35% | ― | 2.83% | -0.71% | |
45 Neutral | S$388.77M | ― | -450.81% | ― | 3.27% | 43.59% | |
43 Neutral | S$51.72M | -1.83 | -47.62% | ― | -1.27% | 16.67% | |
42 Neutral | S$88.41M | -22.47 | -300.34% | ― | ― | ― |
* Healthcare Sector Average
SG:42C
iX Biopharma Ltd.
0.37
0.35
1750.00%
SG:P8A
Cordlife Group
0.15
0.00
0.00%
SG:1J5
Hyphens Pharma International Ltd.
0.35
0.08
29.63%
SG:546
Medtecs International Corporation Ltd.
0.12
<0.01
2.65%
SG:8YY
Biolidics Ltd.
0.05
0.03
168.42%
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.04
<0.01
20.00%
iX Biopharma Ltd. Corporate Events
iX Biopharma Wins US$41 Million U.S. Contract to Advance Wafermine Pain Therapy
Feb 12, 2026
iX Biopharma has secured a US$40.95 million development contract from the U.S. Government, represented by the Defense Health Agency and Program Executive Office Operational Medical Systems, to advance its Wafermine sublingual ketamine wafer for ac...
iX Biopharma Wins US$41 Million U.S. Defense Contract for Non-Opioid Pain Drug
Feb 12, 2026
iX Biopharma has secured a US$40.95 million development contract from the U.S. Department of Defense to advance Wafermine, its patented sublingual ketamine wafer for acute moderate to severe pain, through Phase 3 clinical trials. The funding will ...
iX Biopharma to Raise At Least S$6 Million via Share Placement
Feb 12, 2026
iX Biopharma has entered into a placement agreement with Oversea-Chinese Banking Corporation to raise at least S$6 million through a non-underwritten share placement. The deal will see new ordinary shares offered at S$0.198 each to institutional a...
iX Biopharma Earns Third Spot on Singapore’s Fastest Growing Companies List
Jan 20, 2026
iX Biopharma has been named one of Singapore’s Fastest Growing Companies 2026 by The Straits Times and Statista, marking the third time it has received this recognition after earlier listings in 2023 and 2024, underscoring its strong revenue...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.